The first experience of application of vessel endothelium growth factor inhibitor ranibizumab in complex therapy of retinopathy of premature in URFO in SAHI of the Sverdlovsk region MСMC «Bonum»

Material and methods. The study included 16 patients (31 eyes). Types and terms of treatment. Stage I in the treatment of ROP, laser coagulation of the avascular areas of the retina was performed in three patients with aggressive posterior ROP (4 eyes, 12.9%). In all patients, the progression of the disease was noted. Intravitreal injection of ranibizumab was performed in the period from 8 to 16 weeks (10.5±2.0 weeks), PCV from 32.3 to 39.6 weeks (37.0±1.8 weeks). Result. After laser treatment and IVI of ranibizumab, 11 patients (31 eyes, 81.6%) showed regression of the disease. In 5 patients (6 eyes, 19.4%) - progression. If the ROP progressed, a 25G or 27G lenssparing vitrectomy was performed. Complete regression of ROP was achieved in one patient (1 eye, 16.7%). Partial regression was observed in two patients (2 eyes, 33.3%). In two patients (3 eyes, 50%), the disease progressed to stage 5 with the development of total retinal detachment. Conclusion. As a result of the complex treatment of severe forms of the active stage of retinopathy of prematurity in the regional children's ophthalmological center MKMC "Bonum" in Yekaterinburg, the following data were obtained: complete regression with retinal adhesion is observed in 12 patients (26 eyes, 83.4%), of which in one patient (1 eye, 3.2%) regression was achieved after vitrectomy. Partial regression with the formation of a peripheral retinal detachment after vitrectomy was achieved in two patients (two eyes - 6.5%). Progression of retinopathy of prematurity to stage V with the development of total retinal detachment in two patients (3 eyes, 9.6%). Complex treatment of severe stages of active ROP using laser treatment, IVI and vitrectomy allows to preserve vision in 90.4% of patients. Key words: retinopathy of prematurity; intravitreal injection; laser coagulation of the retina; vitrectomy.

Download Full-text

Application of vessel endothelium growth factor inhibitor ranibizumab in complex therapy of retinopathy of prematurity

Russian Pediatric Ophthalmology ◽

10.17816/rpoj90740 ◽

2021 ◽

Vol 16 (3) ◽

pp. 5-10

Author(s):

M. A. Kariakin ◽

E. A. Stepanova ◽

S. A. Korotkikh ◽

N. S. Timofeeva ◽

S. I. Surtaev

Keyword(s):

Growth Factor ◽

Retinopathy Of Prematurity ◽

Medical Center ◽

Laser Coagulation ◽

Complete Regression ◽

Complex Treatment ◽

Gestation Age ◽

Complex Therapy ◽

Factor Inhibitor

AIM: To conduct a retrospective study of the application of vessel endothelium growth factor inhibitor ranibizumab in complex therapy of retinopathy of prematurity in Ural State children`s ophthalmological center at State Autonomic Health Institution of the Sverdlovsk Region Multiprofile Clinical Medical Center BONUM in Yekaterinburg. MATERIAL AND METHODS: The study included 17 patients (33 eyes). The gestation age was from 23 to 30 weeks (mean: 26.51.7 weeks), birth weight was from 600 to 1850 g (mean: 867229 g). 8 patients (47%) had APROP, and 9 patients (53%) had ROP stage III, type 1, plus disease. Laser coagulation of the avascular areas of the retina as the start in ROP therapy was performed in three patients with APROP (4 eyes, 12.1%). Intravitreal injection of the anti-VEGF ranibizumab was performed in 17 patients (33 eyes), including patients with previous laser coagulation. The age of the patients at the time of injection was from 7.7 to 15.6 weeks (10.51.9 weeks), PCA from 32.3 to 39.6 weeks (37.01.8 weeks). Patients with stage IVa ROP (5 patients, 6 eyes) underwent 25G or 27G lens sparing vitrectomy. RESULTS: As a result of the complex treatment of ROP, the following results were obtained: complete regression in 13 patients (28 eyes, 84.8%). Partial regression in two patients (2 eyes, 6.1%). ROP progression to stage V in two patients (3 eyes, 9.1%). CONCLUSION: Complex treatment of severe stages of active ROP with laser treatment, IVI injections, ranibizumab, and vitrectomy made it possible to preserve vision in 90.9% of patients.

Download Full-text

Involution of Retinopathy of Prematurity After Laser Treatment: Factors Associated With Development of Retinal Detachment

American Journal of Ophthalmology ◽

10.1016/j.ajo.2004.12.106 ◽

2005 ◽

Vol 140 (2) ◽

pp. 214-222 ◽

Cited By ~ 35

Author(s):

David K. Coats ◽

Aaron M. Miller ◽

Mohamed A.W. Hussein ◽

Kathryn M. Brady McCreery ◽

Eric Holz ◽

...

Keyword(s):

Retinal Detachment ◽

Laser Treatment ◽

Retinopathy Of Prematurity ◽

Factors Associated

Download Full-text

Systematic review and meta-analysis of the negative outcomes of retinopathy of prematurity treated with laser photocoagulation

European Journal of Ophthalmology ◽

10.1177/1120672118770557 ◽

2018 ◽

Vol 29 (2) ◽

pp. 223-228 ◽

Cited By ~ 2

Author(s):

Jing Liang

Keyword(s):

Confidence Interval ◽

Laser Treatment ◽

Retinopathy Of Prematurity ◽

Odds Ratio ◽

Laser Photocoagulation ◽

Meta Analysis ◽

Anterior Chamber Depth ◽

Mean Difference ◽

Laser Coagulation ◽

Spherical Equivalent

Introduction: Retinopathy of prematurity is a leading cause of potentially avertable childhood blindness around the world. And laser photocoagulation is currently performed as a gold standard for retinopathy of prematurity treatment, but it may contribute to elevated myopia and decreased visual field. Therefore, the objective of this meta-analysis is to explore the negative impact of laser photocoagulation for retinopathy of prematurity in terms of anatomic outcomes and structural outcomes. Methods: Studies were retrieved through literature searches in PubMed and EMBASE from 1990 to 2017 in English. Case-control studies that reported anatomic and structural changes or significant complications after laser coagulation or cryotherapy for retinopathy of prematurity were eligible. Results: This meta-analysis included eight original studies related to laser treatment for retinopathy of prematurity at any stages. A total of 1422 infants were participated, of which 1156 documented subthreshold or threshold retinopathy of prematurity without laser treatment were selected as comparison group and the rest treated with diode or argon laser coagulation were chosen for experiment group. Taking all included studies into account, spherical equivalent (mean difference −2.53, 95% confidence interval: –5.23 to 0.18, I2 = 96%, P < 0.00001), anterior chamber depth (mean difference −0.52, 95% confidence interval: −0.76 to −0.28, I2 = 55%, P = 0.11), astigmatism (odds ratio 3.19, 95% confidence interval: 1.61 to 6.32, I2 = 0%, P = 0.54), and myopia (odds ratio 8.08, 95% confidence interval: 3.79 to 17.23, I2 = 37%, P = 0.21) were associated with laser treatment for retinopathy of prematurity. Axial length (mean difference −0.01, 95% confidence interval: –0.28 to 0.27, I2 = 0%, P = 0.62) and anisometropia (odds ratio 4.21, 95% confidence interval: 0.54 to 33.17, I2 = 1%, P = 0.31) had no statistical significance on laser coagulation for retinopathy of prematurity. Conclusion: This meta-analysis showed that spherical equivalent, anterior chamber depth, astigmatism, and myopia were associated with the negative outcomes of laser coagulation, while axial length and anisometropia had no statistical importance on the defects of laser coagulation. Therefore, patients treated with laser coagulation should follow periodic cycloplegic refraction and receive early optical correction.

Download Full-text

The frequency of the formation of retinal detachment in the long-term laser treatment of the threshold stages of retinopathy of prematurity

Modern technologies in ophtalmology ◽

10.25276/2312-4911-2020-1-146-149 ◽

2020 ◽

pp. 146-149

Author(s):

О.I. Kashura ◽

◽

M.V. Pshenichnov ◽

О.V. Kolenko ◽

Е.L. Sorokin ◽

...

Keyword(s):

Retinal Detachment ◽

Laser Treatment ◽

Retinopathy Of Prematurity

Download Full-text

Time of vitreal surgery for active retinopathy of prematurity

Acta biomedica scientifica ◽

10.29413/abs.2021-6.6-1.11 ◽

2021 ◽

Vol 6 (6-1) ◽

pp. 96-104

Author(s):

A. V. Tereshchenko ◽

I. G. Trifanenkova ◽

N. N. Yudina ◽

M. S. Tereshchenkova ◽

E. V. Erokhina ◽

...

Keyword(s):

Surgical Treatment ◽

Laser Treatment ◽

Retinopathy Of Prematurity ◽

Surgical Intervention ◽

Laser Coagulation ◽

Optimal Timing ◽

Group 3 ◽

Group 2 ◽

Group 1

Background. The anatomical and functional results of surgery for retinopathy of prematurity (ROP) are determined not only by the stage of the pathological process, but also depend on the timing of its implementation.The aim: to estimate the effectiveness of vitrectomy for severe active retinopathy of prematurity, depending on the timing of surgical treatment.Methods. Vitreoretinal surgery was performed in 138 children (198 eyes) with severe stages of ROP. All patients were divided into three groups depending on the timing of surgical treatment: group 1 – 42–48 weeks of postconceptual age (PCA), with the progression of ROP after laser coagulation of the retina (LCS), group 2 – 39–41 weeks of PCA, with the progression of ROP after LCS, group 3 – 36–39 weeks of PCA, without previous LCS. A 3-port transscleral 27-G vitrectomy was performed by all patients. At the postoperative period, the results of vitrectomy were estimated by the anatomical attachment of the retina. The follow-up period was 12 months. Results. In group 1, in 31 cases (73.8 %), the surgical intervention was completed with silicone tamponade. By the end of the follow-up period, anatomical retinal attachment was achieved in 17 eyes (40.5 %).In group 2, surgical intervention was completed with silicone tamponade in 29 eyes (42 %). By the end of the follow-up period, anatomical retinal attachment was achieved in 52 eyes (75 %).In group 3, surgical intervention was completed with silicone tamponade in 11 of 87 eyes (12.6 %). Anatomical retinal attachment was achieved in 80 eyes (92 %).Conclusion. Untimely vitrectomy (42–48 weeks of PCA) in cases of ROP progression after LCR led to a worse result. If progress of ROP after laser treatment happens, early vitrectomy (39–41 weeks of PCA) should be performed. Primary vitrectomy should be performed in case of the optimal timing of laser treatment has been missed (after 36 weeks of PCV).

Download Full-text

Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity

Journal of American Association for Pediatric Ophthalmology and Strabismus ◽

10.1016/j.jaapos.2010.05.011 ◽

2010 ◽

Vol 14 (5) ◽

pp. 457-459 ◽

Cited By ~ 27

Author(s):

Sun Young Jang ◽

Kyung Seek Choi ◽

Sung Jin Lee

Keyword(s):

Retinal Detachment ◽

Intravitreal Injection ◽

Retinopathy Of Prematurity ◽

Delayed Onset

Download Full-text

EXPERIENCE OF COMBINED LASER TREATMENT IN COMPLICATED PERIPHERAL VITROCHORIORETINAL DYSTROPHIES

UZBEK MEDICAL JOURNAL ◽

10.26739/2181-0664-2021-si-2-9 ◽

2021 ◽

Vol Special issue (2) ◽

pp. 56-60

Author(s):

Azamat Yusupov ◽

◽

Saidakhmad Toshpulatov ◽

Shavkat Mukhanov ◽

Zulfiya Shamsutdinova

Keyword(s):

Optical Coherence Tomography ◽

Retinal Detachment ◽

Laser Treatment ◽

Incidental Findings ◽

Morphological Features ◽

Diagnosis And Treatment ◽

Laser Coagulation ◽

Optical Coherence ◽

Vitreoretinal Interface

Currently, one of the topical subjects of ophthalmology is the study of morphological features of the vitreoretinal interface. Peripheral changes encompass a range of entities, from incidental findings to retinal detachment. Therefore, diagnosis and treatment in the zone of the peripheral interface seem relevant.Keywords: peripheral vitreochorioretinal dystrophy, regmatogenic retinal detachment, inner retinal border membrane, vitreoretinal interface, optical coherence tomography, restrictive retinal laser coagulation, laser tractotomy.

Download Full-text

Treatment outcomes of central retinopathy of prematurity with localization in the Moscow regional perinatal center

Russian Pediatric Ophthalmology ◽

10.17816/rpoj70957 ◽

2021 ◽

Vol 16 (3) ◽

pp. 19-26

Author(s):

A. Y. Panova ◽

A. S. Petrova ◽

S. A. Trusova ◽

O. A. Shevernaya

Keyword(s):

Laser Treatment ◽

Retinopathy Of Prematurity ◽

Promising Result ◽

Antiangiogenic Therapy ◽

Combined Treatment ◽

Posterior Pole ◽

Laser Coagulation ◽

Vegf Inhibitor ◽

Anti Vegf ◽

Perinatal Center

BACKGROUND: Ranibizumab is widely used in retinopathy of prematurity. Therefore, it is necessary to evaluate the effectiveness, the risk of complications, and recurrence of the disease by antiangiogenic therapy. AIM: To demonstrate the experience of using anti-VEGF drugs in the Moscow Regional Perinatal Center and the effectiveness of different approaches to retinopathy of prematurity (ROP) treatment in the central retinal zone. MATERIAL AND METHODS: The case histories of 17 deeply premature infants with threshold ROP stages and localization in the posterior pole were retrospectively analyzed. Children were treated with intravitreal VEGF inhibitor (total 9 children), 5 children underwent laser coagulation of the retina, and 3 children received combined treatment (laser and intravitreal administration of a VEGF inhibitor). RESULTS: The average age of development of threshold stages was 35.2 weeks (range: 30.539 weeks) in our study. The frequency of promising outcomes after using anti-VEGF drugs alone or in conjunction with peripheral laser treatment was 100%. In comparison, the only laser treatment generated a promising result in 70% of the eyes. However, ROP relapses after anti-VEGF therapy developed at 37, 43, 44,5 weeks. In addition, 1 out of 9 children developed a recurrence of ROP and required laser treatment 7 weeks after using anti-VEGF. CONCLUSION: The use of anti-VEGF therapy is an effective method for the treatment of ROP of the posterior pole. However, there is the ambiguity of the available recommendations on the further management of children. Therefore, it is necessary to monitor the children who have received antiangiogenic therapy for as long as possible.

Download Full-text